It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
A HIV vaccine that protects vaccinated individuals from HIV infection is the goal of many HIV research programmes. Currently, there is no effective vaccine against HIV, the virus that causes AIDS. Vaccine development is one of several strategies to reduce the worldwide harm from AIDS, with other approaches based upon antiviral treatments such as highly active antiretroviral therapy (HAART) and social approaches such as safe sex prevention and awareness campaigns.
Classic vaccines mimic natural immunity against reinfection generally seen in individuals recovered from infection; there are almost no recovered AIDS patients.
Most vaccines protect against disease, not against infection; HIV infection may remain latent for long periods before causing AIDS.
Most effective vaccines are whole-killed or live-attenuated organisms; killed HIV-1 does not retain antigenicity and the use of a live retrovirus vaccine raises safety issues.
Most vaccines protect against infections that are infrequently encountered; HIV may be encountered daily by individuals at high risk.
Most vaccines protect against infections through mucosal surfaces of the respiratory or gastrointestinal tract; the great majority of HIV infection is through the genital tract.
An HIV/AIDS vaccine developed at The University of Western Ontario is set for the first phase of human trials.
Sumagen Canada today announced it has submitted an Investigational New Drug application to the United States Food and Drug Administration to begin Phase 1 human trials for its SAV001 AIDS vaccine.
Through Western, Sumagen Canada has secured patents for the vaccine in over 70 countries in the world, including the United States, the European Union and Korea. According to the firm, animal testing has resulted in good antibody reactions in immunology tests, with no adverse effects or safety risks.
London and Western are also on a short list of Canadian cities being considered by the federal government for the building of an $88-million HIV vaccine manufacturing facility. Part of the funding for the facility will come from the Bill and Melinda Gates Foundation.
Originally posted by Unvarnished
reply to post by muzzleflash
I'm in medical school and I can tell you it would be one hell of a risk to take the HIV vaccine, since you're only putting the watered down version of the virus in the body. You'll never know when or how it can reactivate. You sure would not give it to anyone who is immunocompromised.edit on 12-11-2011 by Unvarnished because: (no reason given)
Originally posted by Essan
Because I have no reason to expect that I will ever be at risk of becoming HIV+
Originally posted by Unvarnished
reply to post by muzzleflash
Yep, this is correct, but introducing any foreign material to the body poses a risk of either a crazy immune infection against it where the person could ultimately go into shock, such as an allergic reaction, or into someone who has a weak immune system, where the virus could possibly reactivate. The thing with viruses is that they are not considered dead or alive, they just need a host to replicate themselves, especially cellular machinery that controls both DNA/RNA synthesis. They are just composed of a protein coat that surrounds DNA. If for instance, the DNA mixes and integrates itself with human DNA even if the virus is considered "dead", it can just remain latent there until a specific time where it can reactivate. They infect human CD4 T helper cells, and most of the time patients are asymptomatic until 10-12 years due to its integration into the human genome. Most people do not develop symptoms until after the virus reactivates itself.
Originally posted by Unvarnished
reply to post by RealAmericanPatriot
I agree, the Influenza virus is constantly mutating because of two specific proteins on its surface, known as the hemagluttinin and neuramindase proteins. This is the reason why there is no fully developed flu vaccine.
In a collaborative study with the World Health Organization and seven other laboratories, researchers at the Stanford University School of Medicine have compiled a list of 93 common mutations of the AIDS virus associated with drug resistance that will be used to track future resistance trends throughout the world.
"The epidemic is changing, especially as new drugs are being developed," said Robert Shafer, MD, associate professor of infectious diseases and geographic medicine at Stanford and the senior author of the paper. "To effectively track the spread of drug resistance, particularly transmitted drug resistance, you need a sensitive and specific list that's considered standard and is adopted by all the surveillance studies."